Latest Phase II Data Bolster Cidara’s Antifungal

30 Jul 2019

• By Sten Stovall

Cidara Therapeutics said new top-line results from the Phase II trial evaluating its lead asset as a first-line antifungal treatment in patients with candidemia and invasive candidiasis supported its ongoing Phase III ReSTORE program.

Candida — Rezafungin is a novel echinocandin antifungal being developed as a once-weekly therapy • Source: Shutterstock

Anti-infectives specialist Cidara Therapeutics Inc. said positive top-line data from Part B of its global Phase II STRIVE trial, which evaluated once-weekly use of its lead asset rezafungin acetate compared with once-daily dosing of caspofungin in patients with candidemia and/or invasive candidiasis, bolstered clinical prospects of the antifungal candidate and its ongoing Phase III ReSTORE program.

On 29 July, Cidara said the Phase II STRIVE B trial of the intravenous treatment met all its objectives for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

20 Jun 2025

• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

19 Jun 2025

• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.